On the other hand, mixed-type showed more HCC-like features, such as higher expression levels of AFP, GPC3, APOE, and SALL4. They indicated that therapies for ICC may better suit combined-type cHCC–ICC, whereas therapies for HCC may be adopted to treat mixed-type cHCC–ICC patients. The gene discussed is SALL4; the disease is hepatocellular carcinoma.